April 2019
-
Media ReleaseNovartis starts 2019 with strong sales and double digit core[1] operating income growth, Mayzent launch and Alcon spin-off; profit guidance upgradedTransformation to focused medicines company continued with the spin-off of Alcon; commentary below is on continuing operations2 Continuing operations net sales up 7% (cc1, +2% USD) driven by…
-
Media ReleaseSandoz drives differentiated portfolio with deal to commercialize new treatment for Opioid-Induced Constipation in key European countriesAgreement with Shionogi to commercialize Rizmoic® (naldemedine) in Germany, UK and Netherlands, plus right of first refusal for certain other European markets Rizmoic® is an innovative medicine for…
-
Media ReleaseSandoz resubmits biosimilar pegfilgrastim application to US FDASandoz pursues US approval for biosimilar pegfilgrastim, a long-acting version of supportive oncology medicine filgrastim Pegfilgrastim is used to reduce the incidence of neutropenia, one of the…
March 2019
-
Media ReleaseNovartis announces change in Sandoz leadershipRichard Francis, CEO Sandoz, to step down on March 31, 2019 Francesco Balestrieri, Head Region Europe, Sandoz, appointed ad-interim CEO Sandoz Basel, March 14, 2019 - Novartis announced today that…
-
Media ReleaseThree winners of 2019 Sandoz Healthcare Access Challenge (HACk) are announced at SXSWSandoz commits to increasing support from one winner to three, following impressive pitches from the finalists Winning ideas proposed innovative uses of artificial intelligence, mobile apps and…
January 2019
-
Media ReleaseSandoz certified Global Top Employer 2019Sandoz has been officially certified by the Top Employers Institute for its exceptional employee offerings globally The Top Employers Institute is generally acknowledged as the global authority on…
-
Media ReleaseNovartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018Full year net sales up 5% (cc1, +6% USD) driven by strong performance of growth drivers: Pharmaceuticals BU grew 7% (cc) driven by Cosentyx USD 2.8 billion (+36% cc) and Entresto USD 1.0 billion (+…
-
Media ReleaseSandoz Inc. launches SYMJEPI™ (epinephrine) in the USPrinceton, New Jersey, January 16, 2019 – Sandoz Inc. (Sandoz), a Novartis division, today announced the US market introduction of SYMJEPI™ (epinephrine) 0.3 mg Injection for the emergency treatment…
-
Media ReleaseSandoz selects three finalists for Healthcare Access Challenge (Sandoz HACk) from over 400 global entriesCompetition generated ideas from more than 400 entrants in 80 countries – three shortlisted entrants from Uganda, the US and the Netherlands Three finalists shared innovative uses of artificial…
-
Media ReleaseSandoz and Pear Therapeutics Announce US Launch of reSET-OTM to Help Treat Opioid Use DisorderreSET-O(TM)* is the first US FDA-cleared prescription digital therapeutic for patients with Opioid Use Disorder Cleared by the FDA in December, reSET-O is available immediately As part of a broader…
December 2018
-
Media ReleaseSandoz enters into commercialization and supply agreement for insulin biosimilars, anticipating growing demand as diabetes burden risesAgreement covers biosimilar insulins in early and clinical development for the top three selling branded insulins by sales: glargine, lispro and aspart Over 400 million people worldwide have…
-
Media ReleaseSandoz teams up to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)Strategic collaboration agreement with Curetis subsidiary Ares Genetics to develop digital platform for development and life-cycle management of antibiotics Program will combine established…